Sonoma Pharmaceuticals, Inc. SNOA
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -69.78%
- 1 year
- -72.08%
- Open
- 1.08
- Prev close
- 1.10
- Mkt cap
- 5.27M
- Vol
- 42.06K
- Avg vol
- 107.76K
- EPS
- -1.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.05
- High
- 1.15
- Forward P/E
- -1.49
- Beta
- 1.38
- Short ratio
- 0.22
- Inst. own
- 2.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 13, 2025
- 50-d avg
- 2.82
- 200-d avg
- 3.79
- 1y target
- 19.50
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 7 hours ago |
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
Key statistics
- Market cap
- 3.59M
- Enterprise value
- 569.36K
- Trailing P/E
- 0.00
- Forward P/E
- -1.49
- PEG ratio
- 0.00
- Price / sales
- 0.28
- Price / book
- 0.34
- EPS (TTM)
- -0.99
- Beta
- 1.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -35.91%
- Revenue (TTM)
- 12.70M
- Revenue growth
- -1.10%
- Free cash flow
- -1.70M
- Total cash
- 2.59M
- Total debt
- 420.00K
- Return on equity
- -74.65%
- Shares outstanding
- 1.34M
- Short % of float
- 6.06%
- 50-day average
- 2.82
- 200-day average
- 3.79
Analyst view
Consensus: none
- Target (low)
- 17.00
- Target (mean)
- 19.50
- Target (high)
- 22.00
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 13, 2025
Expected Feb 13, 2025. Consensus EPS estimate -0.60.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 13, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -0.59 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -1.40 | — | — |
| Jun 17, 2024 | Mar 1, 2024 | 0.00 | -1.40 | — | — |
| Feb 8, 2024 | Dec 1, 2023 | 0.00 | -1.20 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -4.00 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 5, 2023 | Ladenburg Thalmann | init | — | Buy |
| Mar 6, 2018 | Maxim Group | down | Buy | Hold |
| Dec 28, 2017 | Benchmark | init | — | Speculative Buy |
| Nov 10, 2017 | Maxim Group | main | — | Buy |
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- sonomapharma.com
News
- Orion OYJ (OTCMKTS:ORINY) & Sonoma Pharmaceuticals (NASDAQ:SNOA) Head to Head Contrast
- Financial Contrast: Sonoma Pharmaceuticals (NASDAQ:SNOA) versus Indivior (NASDAQ:INDV)
- Sonoma Pharmaceuticals (NASDAQ:SNOA) & Harmony Biosciences (NASDAQ:HRMY) Critical Analysis
- Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
- Sonoma Pharmaceuticals Q1 EPS $(0.09) Up From $(0.76) YoY, Sales $6.406M Up From $4.015M YoY
- Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue
- Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue
- Sonoma Pharmaceuticals Receives FDA 510(k) Clearance For Its Microdacyn Wound Irrigation Solution
- Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
- Sonoma Pharmaceuticals Q4 EPS $(0.33) Misses $(0.24) Estimate, Sales $5.561M Miss $5.565M Estimate
Your note
Sign in to keep a note on SNOA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAL POGGETTO JOHN | Officer | Stock Award(Grant) | Jun 19, 2024 | 15,000 |
| DVONCH JEROME J | Chief Financial Officer | Stock Award(Grant) | Jun 19, 2024 | 84,595 |
| THORNTON BRUCE | Officer | Stock Award(Grant) | Jun 19, 2024 | 154,411 |
| TROMBLY AMY MOSS | Chief Executive Officer | Stock Award(Grant) | Jun 19, 2024 | 153,586 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.95% | 12,730 | 34.12K | Sep 29, 2024 |
| Ground Swell Capital, LLC | 0.78% | 10,400 | 27.87K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.31% | 4,141 | 11.10K | Sep 29, 2024 |
| Citigroup Inc. | 0.01% | 180 | 482 | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.01% | 138 | 369 | Sep 29, 2024 |
| Blackrock Inc. | 0.01% | 113 | 302 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.40% | 5,342 | 14.32K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.19% | 2,528 | 6.78K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 1,881 | 5.04K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 248 | 664 | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.01% | 190 | 509 | Sep 29, 2024 |